الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 219 |  |  |
| | | from | 219 | | |
Abstract
Objective: Thiazoles are naturally occurring heterocyclic compounds that include nitrogen and sulphur and have a variety of therapeutic characteristics. (IVASB1) known as 3-(Thiazol-2-ylimino)methyl)vanillyl-2-methylimidazolium chloride, (IVASB2) known as 2,5-Bis-(5-(2-methylimidazolium chloride)-3- methoxysalicylideneimino)-1,3,4-thiadiazole, and (IVASB3) known as 2,5-Bis-(5- (2,4-lutidinium chloride)-3- methoxysalicylideneimino)-1,3,4-thiadiazole are new synthesized heterocyclic compounds by Prof. Dr. Reda Fathy Elshaarawy in chemistry department faculty of science Suez university. The current study aims to assess the anticancer activity of certain novel heterocyclic compounds against Ehrlich solid tumour (EST) in Swiss albino mice. Materials and Methods: The docking test was evaluated for the test compounds. The antitumor efficacy of (IVASB1), (IVASB2), and (IVASB3) was first tested on human breast cancer cell lines (MCF-7), and the IC50 for each drug was found. The anticancer efficacy of IVASB1, IVASB2, and IVASB3 against EST was next tested in Swiss albino mice. The anticancer impact of the test drugs was evaluated using hematological, flowcytometric, and biochemical data from an EST-bearing host. The histopathological examination was also assessed. Results: Treatment with (IVASB1), (IVASB2), and (IVASB3) chemicals restored the hematological profile counts of Complete blood components (CBC) to normal. Flowcytometric study has revealed that cell cycle arrest occurs more frequently in the S phase and leads to apoptosis. Histopathological sections of the liver from EST control mice revealed several abnormalities when compared to normal ones. IVASB3 is the most potent anti-breast cancer contender (IC50 3.73 ± 0.2 g/mL) due to its high binding energy score (3.433 kcal/mol). Cell cycle research revealed that 2 2 IVASB 3 enhanced the percentage of EST cells in the sub G1 phase while decreasing the percentage of cells in the S phase. Furthermore, injection of IVASB 1, IVASB 2, and IVASB 3 to tumorized animals reduced cyclin-dependent kinase-1 (CDK1) expression by 41.27 percent, 53.31 percent, and 78.57 percent, respectively. Furthermore, levels of poly ADP-ribose polymerase (PARP) and vascular endothelial growth factor (VEGF) were significantly lower in the serum of tumorized animals given IVASBs. As a result, the anticancer effects of IVASBs may be ascribed to their ability to reduce CDK1, PAPR, and VEGF expression. Conclusion: The test compounds were found to have significant anticancer activity against Ehrlich solid tumour, comparable to that of 5 fluorouracil.